01/19/23 8:00 AMNasdaq : VOR conferencesclinical triallow floatVor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem MeetingsVor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33)RHEA-AIneutral
01/12/23 8:00 AMNasdaq : VOR conferenceslow floatVor Bio to Present at B. Riley Securities’ 3rd Annual Oncology ConferenceVor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference. B. Riley Securities’ 3rd Annual Oncology Conference –RHEA-AIneutral
12/07/22 7:45 AMNasdaq : VOR offeringlow floatVor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 MillionVor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million. In the underwrittenRHEA-AIneutral
12/07/22 7:30 AMNasdaq : VOR low floatFirst AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™Vor Bio (Nasdaq: VOR),RHEA-AIneutral
11/22/22 8:00 AMNasdaq : VOR conferenceslow floatVor Bio to Participate in Upcoming Investor ConferencesVor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Piper Sandler 34th Annual Healthcare Conference Presentation: Tuesday, NovemberRHEA-AIneutral
11/10/22 4:15 PMNasdaq : VOR earningslow floatVor Bio Reports Third Quarter 2022 Financial Results and Provides Company UpdateVor Bio (Nasdaq: VOR), a clinical-stage cell and genomeRHEA-AIneutral
11/01/22 8:00 AMNasdaq : VOR conferenceslow floatVor Bio to Participate in Upcoming Investor ConferencesVor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Credit Suisse 31st Annual Healthcare Conference A virtual presentation will beRHEA-AIneutral
10/12/22 8:00 AMNasdaq : VOR managementlow floatVor Bio Appoints Eyal C. Attar, M.D. as Chief Medical OfficerVor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinical experience toRHEA-AIvery positive
10/11/22 8:00 AMNasdaq : VOR low floatVor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European Society of Gene & Cell Therapy (ESGCT) Annual Congress CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBERHEA-AIneutral
09/28/22 8:00 AMNasdaq : VOR low floatVor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA HeadquartersVor Bio (Nasdaq: VOR), a clinical-stage cell andRHEA-AIvery positive